29 results about "Lipid binding" patented technology

Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.

Disclosed herein are methods for treating eye diseases, for example eye diseases associated with lipid accumulation, with lipid binding protein-based complexes such as CER-001; lipid binding protein-based complexes, compositions comprising a lipid binding protein-based complex as a carrier for one or more ophthalmic drugs, and uses thereof.

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

Methods of using lipid binding protein molecules to treat a subject having or at risk of one or more conditions, such as sepsis (e.g., septic shock).

The present invention relates to a method for reducing lipid binding of brazzein and / or to method for improving digestibility of brazzein in a subject's digestive track as well as to a modified brazzein polypeptide and uses of it and to a nucleic acid encoding the same.

The invention relates to a vaccine platform, comprising a lipid binding amino acid sequence and an oligomerization sequence. In particular, the lipid binding amino acid sequence and an oligomerization sequence are derived from filensin, a protein with no or minimal immunogenicity. Filensin has an extremely strong membrane binding capacity and oligomerization property, making it an ideal carrier for an antigenic moiety. An immunization platform comprising a nucleic acid sequence(s) coding for a lipid binding amino acid sequence and an oligomerization sequence is also provided.

An in vitro method of detecting one or more endotoxins of one or more pathogens in a sample, comprising the steps of a. coating a lipid binding protein on a substrate or capturing a lipid binding protein on a capture molecule immobilized on a substrate, b. contacting the lipid binding protein, thus coated or captured, with the sample, c. detecting whether an endotoxin binds to the lipid binding protein, wherein the one or more endotoxins comprise a lipid A moiety and O- polysaccharide moiety, wherein the lipid binding protein is capable of binding the lipid A moiety of an endotoxin, and characterized in that the lipid binding protein is a mammalian protein and preferably is a murine or human protein.

[Problem] To provide, inter alia, an information processing system with which it is possible to accurately estimate binding force to lipid [Solution] According to one aspect of the present invention, provided is an information processing system comprising a processor configured to execute the next steps by reading a program. In an acquisition step, an amino acid sequence for which an inference is to be carried out is acquired. In an inference step, the binding force, to lipid, of a protein having the amino acid sequence for which an inference is to be carried out is inferred on the basis of the amino acid sequence for which an inference is to be carried out, and reference information. The reference information includes a correlation between the amino acid sequence and the binding force, the correlation being constructed on the basis of actually measured values of the binding force.

This invention relates to the fields of environmental and bioanalytical technology, and particularly to a method for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. The technical solution includes a framework process for simultaneous pretreatment and detection of bisphenol S and bisphenol AF in biological tissues. This invention establishes a dual-solvent secondary extraction system composed of n-hexane and methyl tert-butyl ether, achieving differentiated adaptation to different tissue matrices. By combining the advantages of non-polar and moderately polar solvents, it can simultaneously handle the relatively highly polar bisphenol S and the relatively non-polar bisphenol AF in a single extraction process. Furthermore, this method sets key physical parameters during the extraction process according to the histological characteristics of each organ. For heart and lung tissues, specific ultrasonic power is used to ensure thorough cell disruption; while for liver and spleen with high lipid content, different power and time are used to ensure the full release of lipid-bound target substances.

Methods for treating acute conditions (e.g., acute conditions comprising acute inflammation), such as cytokine release syndrome, sepsis and acute kidney injury using lipid binding protein-based complexes.

A method for detection or monitoring status of traumatic brain injury (TBI) and / or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP / FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP / FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

The invention relates to an engineering lipoid transporter carrier for efficient hydrophobic drug delivery and a preparation method and application thereof, and belongs to the technical field of biological medicine. The carrier disclosed by the invention is a carrier based on Bla g 1 protein mutation, and the mutant protein has three repetitive units consisting of 100-180 amino acids, so that a spherical structure with a hydrophobic inner cavity is formed. By simulating the lipid binding and transporting mechanism of human apoA-I / MSP, efficient encapsulation of hydrophobic drugs is achieved, the solubility and bioavailability of the drugs are remarkably improved, and toxic and side effects are reduced. The B1a g 1 protein carrier has a simple preparation method, large-scale production can be realized through recombinant protein engineering, and an efficient and safe new strategy is provided for delivery and clinical application of indissolvable drugs.

Methods for treating leukocytosis, endothelial dysfunction, and carditis comprising administering to a subject a lipid binding protein-based complex.

The present invention relates to monoclonal antibodies to the HCV core lipid binding domain. The present invention provides monoclonal antibodies for detecting Hepatitis C Virus (HCV) antigens. The antibodies specifically immunoreact with at least one epitope of the lipid binding domain of amino acid residues 134-171 of the HCV core antigen. Further provided are immunoassay methods for detecting HCV infection using the antibodies, kits comprising the antibodies, and compositions.

Methods of using a lipid binding protein molecule to treat a subject having one or more conditions or at risk of one or more conditions. The method generally includes measuring ApoA-I levels and / or HDL cholesterol levels in the subject, and administering one or more doses of the lipid binding protein molecule to the subject if the measured ApoA-I levels are below a target ApoA-I level or target ApoA-I range, and / or the measured HDL levels are below a target HDL level.

The invention discloses application of morusin O in preparation of a TEAD protein palmitoylation inhibitor, and relates to the technical field of molecular biology. The invention also provides a TEAD palmitoylation inhibitor and a method for screening the TEAD palmitoylation inhibitor in vitro. It is found for the first time that the compound can be directly combined with a lipid binding pocket of TEAD1 protein to interfere the post-translational palmitoylation modification level of the TEAD1 protein, so that the conformational stability and transcriptional activity of TEAD1 are reduced, and the application value is wide.

A lipid-binding protein comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the glycine residue at position 12 from the N-terminus of the amino acid sequence of SEQ ID NO: 1 is substituted with an amino acid residue selected from the group consisting of cysteine, valine, leucine, isoleucine, alanine, and methionine, and wherein the lipid-binding protein has a higher binding affinity for PI(3,5)P₂ than a protein consisting of the amino acid sequence of SEQ ID NO: 1.

An in vitro method of detecting one or more endotoxins of one or more pathogens in a sample, comprising the steps of a. coating a lipid binding protein on a substrate or capturing a lipid binding protein on a capture molecule immobilized on a substrate, b. contacting the lipid binding protein, thus coated or captured, with the sample, c. detecting whether an endotoxin binds to the lipid binding protein, wherein the one or more endotoxins comprise a lipid A moiety and O- polysaccharide moiety, wherein the lipid binding protein is capable of binding the lipid A moiety of an endotoxin, and characterized in that the lipid binding protein is a mammalian protein and preferably is a murine or human protein.

This disclosure provides therapeutic nanodiscs comprising a lipid-binding polypeptide, a lipid bilayer, and a therapeutic agent, wherein the therapeutic agent may be used to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries. The lipid bilayer may be 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), and the therapeutic agent may be a nucleic acid polymer. Furthermore, methods for administering therapeutic nanodiscs to treat, prevent, or diagnose central nervous system diseases, disorders, injuries, or injuries, as well as the use of such therapeutic nanodiscs, are provided.

Methods for treating hyperinflammatory conditions such as hemophagocytic lymphohistiocytosis (HLH), dengue hemorrhagic fever, and dengue shock syndrome using lipid binding protein-based complexes.

A fusion protein formed by a conditionally-activated lipid-binding domain that exposes a lipid moiety in response to a stimulus that is fused to a stimulus-responsive polypeptide domain. An exemplary conditionally-activate domain, a prototypical myristoyl switch, was fused with a thermo-responsive coil-protein. Biophysical characterizations confirmed the integrity and functionality of recoverin's myristoyl-switch within the fusion protein. Dynamic light scattering and cryo-TEM demonstrated that liposwitching modulates temperature-triggered phase separation and the hierarchical assembly of the fusion proteins. The fusion protein can therefore respond emergently to biologically relevant signals in a manner that mirrors the adaptability of riboswitches

The invention belongs to the field of functional food and natural product chemistry, and particularly relates to a polygonatum sibiricum tea composition with a lipid regulating function and a preparation method of the polygonatum sibiricum tea composition. The composition is prepared from a modified rhizoma polygonati extract, 4-hydroxy-3-methoxyphenylpyruvic acid, green tea powder, lotus leaf powder, malt flour and a fructus momordicae extract. The modified polygonatum sibiricum extract is prepared by modifying a polygonatum sibiricum extracting solution through a gallic acid-L-serine deep eutectic system, an esterification and hydrogen bond recombination structure is formed in the modification process, and the hydrophobicity, the oxidation resistance and the lipid binding capacity of polygonatum sibiricum polysaccharide are remarkably improved. 4-hydroxy-3-methoxyphenylpyruvic acid is used as natural aromatic organic acid, and has a synergistic effect with the modified rhizoma polygonati extract, so that cholesterol excretion can be promoted, and lipid peroxidation can be inhibited. The composition disclosed by the invention has excellent performance in the aspects of reducing serum cholesterol and triglyceride, improving the free radical scavenging rate and maintaining the stability of the tea powder, is obviously superior to an unmodified or single modified system, and has structural innovation and a good application prospect.

Methods of treating excessive inflammatory conditions, such as hemophagocytic lymphocyte hyperplasia (HLH), dengue hemorrhagic fever, and dengue shock syndrome, using lipid binding protein based complexes.

A combination of a lipid-binding molecule and / or a lipid-binding protein and a lipid component (i.e., mispid) for modulating the interaction of a target molecule with a lipid membrane is provided. This includes, for example, the use of the lipid binding molecules and / or mispid to improve the sequencing efficiency and flux of nanopore-based sequencing systems. For sequencing a target molecule, such as a nucleic acid sequence or a substitute nucleic acid polymer derived therefrom, a lipid-binding molecule and / or a mispid thereof is combined with the target molecule. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of the lipid-binding molecules and / or nanodisks, thereby improving capture, time of arrival and effective concentration of the target molecules across the membrane of the chip. This improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.

The invention discloses a preparation method and application of a near-infrared fluorescent probe for specifically recognizing foam cells, and relates to the technical field of fluorescent probes. The probe adopts an electron donor-conjugated olefinic bond-electron acceptor (D-pi-A) molecular architecture, the lipid binding capacity is enhanced through a dihexylaminobenzene unit, 705nm near-infrared emission is realized through a pyridinium group, and the membrane binding stability is improved by combining with a double positive charge group. The probe has the characteristics of no washing and rapid marking, living cell imaging can be completed within 5 minutes, the fluorescence intensity is enhanced by 42.5 times in a lipid environment, and foam cells and normal macrophages can be specifically distinguished. Compared with a traditional oil red O staining technology, the method has the advantages that real-time dynamic monitoring of the foam cell generation process is realized in a breakthrough manner, and a novel molecular tool is provided for atherosclerosis early pathological mechanism research, drug curative effect evaluation and clinical diagnosis.

The present invention provides compounds used for the treatment of acute conditions including sepsis, sepsis-associated AKI, ischemia / reperfusion AKI, and CSA AKI, as well as CRS, such as CRS associated with immunotherapy and CRS secondary to infections like COVID-19. [Solution] A lipid-binding protein-based complex is provided for use in a method of treating an acute condition, the method comprising the step of administering a high dose of the lipid-binding protein-based complex to a subject in need thereof, the acute condition may include acute inflammation.

An assay and kit for detecting N-retinylidene-N-retinylethanolamine (A2E) in a sample that uses a lipid binding protein, such as Saposin B, to capture A2E in the sample and assist in the extraction and measurement of A2E via mass spectroscopy. A2E thus serves as a marker for macular degeneration so that the assay and kit of the invention can be used to detect the presence or severity of macular degeneration.